Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma
…, I Espinoza-Delgado, MR Baer, JL Holleran… - Clinical Cancer …, 2009 - AACR
Purpose: Vorinostat, a histone deacetylase inhibitor, enhances cell death by the proteasome
inhibitor bortezomib in vitro. We sought to test the combination clinically. Experimental …
inhibitor bortezomib in vitro. We sought to test the combination clinically. Experimental …
Preclinical toxicity of a geldanamycin analog, 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG), in rats and dogs: potential clinical relevance
…, JM Covey, MJ Egorin, JL Eiseman, JL Holleran… - Cancer chemotherapy …, 2005 - Springer
Purpose 17-DMAG is a hydrophilic derivative of the molecular chaperone inhibitor 17-(allylamino)-17-demethoxygeldanamycin
(17-AAG; NSC-330507), which is currently being …
(17-AAG; NSC-330507), which is currently being …
Plasma pharmacokinetics, oral bioavailability, and interspecies scaling of the DNA methyltransferase inhibitor, zebularine
JL Holleran, RA Parise, E Joseph, JL Eiseman… - Clinical cancer …, 2005 - AACR
Purpose: Zebularine is a DNA methyltransferase inhibitor proposed for clinical evaluation.
Experimental Design: We developed a liquid chromatography/mass spectrometry assay and …
Experimental Design: We developed a liquid chromatography/mass spectrometry assay and …
Phase I study of decitabine in combination with vorinostat in patients with advanced solid tumors and non-Hodgkin's lymphomas
…, W Zhang, I Espinoza-Delgado, JL Holleran… - Clinical Cancer …, 2011 - AACR
Purpose: This phase I study evaluated the safety, tolerability, pharmacokinetics, and preliminary
efficacy of the combination of decitabine with vorinostat. Patients and Methods: Patients …
efficacy of the combination of decitabine with vorinostat. Patients and Methods: Patients …
[HTML][HTML] Phase I pharmacokinetic and pharmacodynamic study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin, an inhibitor of heat-shock protein 90, in …
…, SS Ramalingam, C Naret, JL Holleran… - Journal of clinical …, 2010 - ncbi.nlm.nih.gov
Purpose To define the maximum tolerated dose, toxicities, pharmacokinetics, and
pharmacodynamics of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17DMAG). …
pharmacodynamics of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17DMAG). …
A phase I, pharmacokinetic and pharmacodynamic study on vorinostat in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with refractory …
…, A Litwin, YM Rustum, ME Ross, JL Holleran… - Clinical cancer …, 2009 - AACR
Purpose: We conducted a phase I study to determine the maximum tolerated dose of
vorinostat in combination with fixed doses of 5-fluorouracil (FU), leucovorin, and oxaliplatin (…
vorinostat in combination with fixed doses of 5-fluorouracil (FU), leucovorin, and oxaliplatin (…
NCI comparative oncology program testing of non-camptothecin indenoisoquinoline topoisomerase I inhibitors in naturally occurring canine lymphoma
…, H Wilson-Robles, J Tomaszewski, JL Holleran… - Clinical Cancer …, 2018 - AACR
Purpose: Only one chemical class of topoisomerase I (TOP1) inhibitors is FDA approved,
the camptothecins with irinotecan and topotecan widely used. Because of their limitations (…
the camptothecins with irinotecan and topotecan widely used. Because of their limitations (…
Clinical and pharmacologic evaluation of two dosing schedules of indotecan (LMP400), a novel indenoisoquinoline, in patients with advanced solid tumors
…, JL Holleran, JH Beumer, L Rubinstein… - Cancer chemotherapy …, 2016 - Springer
Purpose Indenoisoquinolines are non-camptothecin topoisomerase I (TopI) inhibitors that
overcome the limitations of camptothecins: chemical instability and camptothecin resistance. …
overcome the limitations of camptothecins: chemical instability and camptothecin resistance. …
A liquid chromatography–electrospray ionization tandem mass spectrometric assay for quantitation of the histone deacetylase inhibitor, vorinostat (suberoylanilide …
RA Parise, JL Holleran, JH Beumer… - … of Chromatography B, 2006 - Elsevier
Vorinostat (suberoylanilide hydroxamic acid, SAHA) is undergoing evaluation as an
antineoplastic agent. We developed a liquid chromatography–tandem mass spectrometry (LC–MS/…
antineoplastic agent. We developed a liquid chromatography–tandem mass spectrometry (LC–MS/…
Simultaneous quantitation of abiraterone, enzalutamide, N-desmethyl enzalutamide, and bicalutamide in human plasma by LC–MS/MS
…, RA Parise, JL Holleran, LD Lewis, L Appleman… - … of pharmaceutical and …, 2017 - Elsevier
Inhibiting the androgen receptor (AR) pathway is an important clinical strategy in metastatic
prostate cancer. Novel agents including abiraterone acetate and enzalutamide have been …
prostate cancer. Novel agents including abiraterone acetate and enzalutamide have been …